ArticleBlood2020
A bispecific approach to improving CAR T cells in AML.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Emerging Immunotherapy Approaches for Treating Prostate Cancer.International journal of molecular sciences · 2023Review
- Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia.Cancers · 2023Review
- Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy.Advances in experimental medicine and biology · 2023Article
- Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.Stem cell reviews and reports · 2021Review
- Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.Current treatment options in oncology · 2021Review
- Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!Advances in experimental medicine and biology · 2021Article
- Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?Frontiers in oncology · 2020Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32135017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.